tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate | 1261238-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate
• 英文别名: tert-butyl N-[5-(3,4-diaminophenoxy)pentyl]carbamate
• CAS: 1261238-08-7
• 化学式: C₁₆H₂₇N₃O₃
• 分子量: 309.409
• InChiKey: UOAGAEGUANPLCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  99.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  二硫化碳 、 tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate 在 potassium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 以50%的产率得到tert-butyl 5-(2-mercapto-1H-benzo[d]imidazol-5-yloxy)pentylcarbamate
  参考文献：
  名称：

  Synthesis of a DOTA (Gd3+)-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies

  摘要：

  Magnetic resonance imaging (MRI) is used to evaluate gastrointestinal (GI) structure and functions in humans. Despite filling the viscus lumen with a contrast agent, visualization of the viscus wall is limited. To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to proton pumps in the stomach and colon. The DOTA linkage was installed at a mechanism-based strategic location in the pantoprazole molecule to minimize a possible negative effect of the structural modification on the drug. It is anticipated that by defining the wall of the stomach and colon, this compound will facilitate functional MRI of the GI tract in humans. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.051
• 作为产物：
  描述：

  5-(N-叔丁氧羰基氨基)-1-戊醇 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 三乙胺 、 potassium iodide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.5h， 生成 tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate
  参考文献：
  名称：

  Synthesis of a DOTA (Gd3+)-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies

  摘要：

  Magnetic resonance imaging (MRI) is used to evaluate gastrointestinal (GI) structure and functions in humans. Despite filling the viscus lumen with a contrast agent, visualization of the viscus wall is limited. To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to proton pumps in the stomach and colon. The DOTA linkage was installed at a mechanism-based strategic location in the pantoprazole molecule to minimize a possible negative effect of the structural modification on the drug. It is anticipated that by defining the wall of the stomach and colon, this compound will facilitate functional MRI of the GI tract in humans. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.051

文献信息

• IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY
  申请人：Bharucha Adil E.

  公开号：US20120107248A1

  公开（公告）日：2012-05-03

  This disclosure relates to contrast agents and compositions comprising the same that are capable of blocking the hydrogen/potassium adenosine triphosphatase enzyme system, and more particularly to the use of such compositions for imaging stomach and colon volume and motility.

  本公开涉及对比剂和包含其的组合物，其能够阻止氢/钾腺苷三磷酸酶系统，更具体地，涉及使用这种组合物来成像胃和结肠的容积和运动性能。
• [EN] IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY<br/>[FR] IMAGERIE DES VOLUMES ET DE LA MOTILITÉ GASTRO-INTESTINAUX
  申请人：MAYO FOUNDATION

  公开号：WO2011005609A2

  公开（公告）日：2011-01-13

  This disclosure relates to contrast agents and compositions comprising the same that are capable of blocking the hydrogen/potassium adenosine triphosphatase enzyme system, and more particularly to the use of such compositions for imaging stomach and colon volume and motility.